查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2052622

僵直性脊椎炎（AS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Ankylosing Spondylitis (AS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計到 2035 年，德國僵直性脊椎炎市場規模將從約 12 億美元成長到 21 億美元。
  • 市場成長受以下因素支撐：
  • 生物製藥和標靶治療的應用日益廣泛
  • 人們對這種疾病的認知不斷提高，早期診斷也取得了進展。
  • 市場規模的擴大是由治療週期長和高品質治療方案的出現所推動的。
  • 未來的成長取決於下一代免疫調節療法和個人化治療策略。

僵直性脊椎炎（AS）概述

僵直性脊椎炎是一種慢性免疫介導的脊椎關節病，與HLA-B27密切相關，其特徵是肌腱端炎、骶髂關節炎以及由TNF和IL-17通路失調引起的進行性椎體融合。此病表現為逐漸加重的發炎性腰痛、晨僵（活動後可緩解）以及不同程度的周邊關節、眼部和心臟受累。診斷需結合臨床標準、薦髂關節炎的MRI觀察及HLA-B27檢測結果。疾病嚴重程度的評估包括結構進展以及ASDAS和BASDAI評分。非類固醇抗發炎藥（NSAIDs）是首選治療藥物，但對於難治性疾病，可使用TNF抑制劑、IL-17A/F雙重抑制劑（如比美珠單抗）或JAK抑制劑（如Upadacitinib）。定期進行關節活動度評估和心血管篩檢是後續觀察的指南。早期先進的治療、物理治療和病患教育可以維持病患的功能和生活品質。

主要亮點

  • 根據預測，德國僵直性脊椎炎患者人數將從 2025 年的約 202,963 人增加到 2035 年的 216,565 人。
  • 僵直性脊椎炎是一種慢性發炎性疾病，會導致進行性脊髓損傷和運動功能下降。
  • 早期診斷和治療對於減緩結構性病變進展和維持身體機能至關重要。
  • 生物製藥和標靶治療已顯著改善了疾病的治療效果。
  • 持續性疾病活動和診斷延遲仍然是主要的臨床挑戰。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Shenzhen Huishan Biotechnology Co., Ltd.
  • Lynk Pharmaceuticals Co., Ltd.
  • Sunshine Guojian Pharmaceutical（Shanghai）Co., Ltd.
  • SPH-BIOCAD（HK）Limited
  • UCB Biopharma SRL
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Akeso
  • Janssen Research &Development, LLC
  • Biocad
  • Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
  • Johnson &Johnson Private Limited
  • AbbVie
  • XBiotech, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

  • 主要未滿足的需求及其未來透過新興治療方法實現的可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Ankylosing Spondylitis (AS) Market Outlook

Thelansis's "Ankylosing Spondylitis (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ankylosing Spondylitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ankylosing Spondylitis (AS) Overview

Ankylosing Spondylitis is a chronic immune-mediated spondyloarthropathy strongly associated with HLA-B27, characterized by enthesitis, sacroiliitis, and progressive spinal fusion driven by TNF and IL-17 pathway dysregulation. It presents with insidious inflammatory back pain, morning stiffness improving with activity, and variable peripheral joint, ocular, and cardiac involvement. Diagnosis combines clinical criteria, MRI sacroiliitis, and HLA-B27 testing; ASDAS and BASDAI scores alongside structural progression gauge severity. NSAIDs remain first-line; refractory disease warrants TNF inhibitors, IL-17A/F dual blockade with bimekizumab, or JAK inhibitors including upadacitinib. Regular mobility assessment and cardiovascular screening guide monitoring. Early advanced therapy, physiotherapy, and patient education preserve function and quality of life.

Key Highlights

  • In Germany, the diagnosed ankylosing spondylitis patient pool is projected to increase from approximately 202,963 in 2025 to 216,565 by 2035.
  • Ankylosing spondylitis remains a chronic inflammatory disease causing progressive spinal damage and reduced mobility.
  • Early diagnosis and treatment are essential to slowing structural progression and preserving physical function.
  • Biologic therapies and targeted treatments have significantly improved disease outcomes.
  • Persistent disease activity and delayed diagnosis continue to represent key clinical challenges.

Market Overview

  • The Germany ankylosing spondylitis market is projected to grow from approximately $1.2 BN to $2.1 BN by 2035.
  • Market growth is supported by:
  • Increasing adoption of biologics and targeted therapies
  • Growing awareness and earlier disease diagnosis
  • Market value growth is driven by long-term treatment duration and premium therapeutic options.
  • Future growth will depend on next-generation immunomodulatory therapies and personalized treatment strategies.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Shenzhen Huishan Biotechnology Co., Ltd.
  • Lynk Pharmaceuticals Co., Ltd.
  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
  • SPH-BIOCAD (HK) Limited
  • UCB Biopharma SRL
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Akeso
  • Janssen Research & Development, LLC
  • Biocad
  • Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
  • Johnson & Johnson Private Limited
  • AbbVie
  • XBiotech, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)